FDA moves ahead with safety study of abortion pill mifepristone

TL;DR

The FDA is conducting a safety study of the abortion pill mifepristone.
This study could lead to restrictions on the medication's access.
The study is retrospective and involves hundreds of thousands of cases.
Interim results may be released in July, with final results depending on further analysis.
The Biden administration lifted restrictions on mifepristone, allowing telehealth and mail delivery, which has faced legal challenges.
Planned Parenthood CEO Alexis McGill Johnson called the review a "politically motivated farce" and expressed concern about the Trump administration attempting to limit abortion access.
While a ban is unlikely, the study's findings could limit access through telehealth or mail, or restrict prescribing authority.

Weiter zum Originalartikel